From January 1984 to December 1994, ABMT was performed on 154 children (101 males, 53 females; median age 10, range 3-21 years) with ALL and registered for BMT by the AIEOP (Italian Association of Paediatric Haemato-Oncology). All patients were in CR: 98 were in 2nd CR and 56 were in Ͼ2nd CR. Fifteen children (9.7%) died of transplant-related mortality. Ninety-five patients (61.6%) relapsed at a median of 5 (range 1-42) months after ABMT. The 8-year EFS according to pre-BMT status was 34.6% (s.e. 4.9) for 2nd CR patients and 10.6% (s.e. 5.6) for patients in Ͼ2nd CR. By univariate analysis, site of relapse (isolated extramedullary (IE) vs BM: EFS = 68.5% vs 18.2%; P Ͻ 0.0001) and TBI containing regimen (TBI vs no TBI: EFS = 48.1 vs 15.4%; P = 0.0023) were significant factors for 2nd CR patients. When the 2nd CR subset with BM involvement was analysed, TBI became insignificant (EFS = 25.4 vs 11.8%). No factors influenced EFS in patients in Ͼ2nd CR. By multivariate analysis, site of relapse was the only significant factor in 2nd CR patients (P Ͻ 0.0001). In conclusion, ABMT is an effective treatment after one early IE relapse. Few patients can be rescued after BM relapse. Keywords: childhood ALL; ABMT; BM relapse; isolated extramedullary relapse The introduction of intensive front-line therapy has improved the EFS for childhood ALL.
relapse, most children develop BM relapse or refractory CNS leukemia. [7] [8] [9] [10] [11] After a testicular relapse, the reported 3-year EFS with conventional retreatment depends on the time of relapse: 20% for patients relapsing on therapy, 12, 13 40% for patients relapsing during the first year after stopping therapy, 13, 14 and 100% for patients who relapse later. 13 Following a 2nd relapse, the likelihood of prolonged EFS is further diminished. Allogeneic BMT, from an HLAidentical sibling [15] [16] [17] or unrelated donor, 18 seems to be the treatment of choice following an early BM relapse. Unfortunately, only 25-30% of children has a family donor and it is not always possible to find a fully compatible or minor mismatched unrelated donor despite the increased size of bone marrow donor panels. The role of BMT after an early isolated extramedullary (IE) relapse is less clear. 19, 20 In order to investigate whether ABMT could represent an alternative option for children lacking an HLA-identical donor, [21] [22] [23] we retrospectively analysed 154 ALL patients who underwent ABMT with varying remission status.
Patients and methods
From January 1984 to December 1994, 154 ALL children in 2nd or subsequent CR underwent ABMT at 10 Italian paediatric BMT centres. The relevant data were collected by the AIEOP-BMT Registry via oriented reporting forms completed by the physician in charge at each BMT Centre. The front-line treatment was according to the AIEOP protocols of the 82, 85, 87, 88 series, including intrathecal therapy and/or cranial irradiation. [24] [25] [26] BFM criteria were used for the definition of isolated or combined bone marrow relapse and IE relapse. 5 Second-line treatment was given either according to the AIEOP protocols or on the basis of the modified BFM multiple drug protocol. 5, 27, 28 Criteria for choosing ABMT were an early relapse (within 30 months of diagnosis) or high-risk group at diagnosis, or multiple relapses, lack of any suitable matched donor, and morphological remission before transplant. Table 1 shows the conditioning regimens. Fractionated TBI was administered by linear accelerator at a median dose rate of 17 cGy/min BU = busulfan; CY = cyclophosphamide; VCR = vincristine; TBI = total body irradiation; Ara-C = cytosine arabinoside.
(range 4.6-41) to a total dose of 12 Gy (200 × 2 over 3 days) or 14.4 Gy (120 × 3 over 4 days). Eleven patients underwent a boost (12 Gy): seven to the testes, four to the CNS. In vitro pharmacological marrow purging was done with Asta-Z at standard dose of 1 g/ml, or vincristine and prednisolone. 29, 30 Patients were hospitalised in laminar airflow or Hepa-filtered rooms and received antimicrobial prophylaxis with non-absorbable antibiotics as intestinal decontamination. Prophylactic acyclovir and fluconazole were adopted systematically as of 1991.
Sex, age, duration of 1st CR (in months) and data regarding purging and TBI for patients who underwent ABMT are summarised in Table 2 . For analysis, patients have been divided into number of relapses (2nd CR and Ͼ2nd CR) and into site of relapse (isolated or combined BM relapse and IE relapse).
2nd CR group: Ninety-eight patients underwent ABMT in 2nd CR (our group has already reported on 75 of these 31 ); 65 had experienced an isolated (n = 46) or combined (n = 19) BM relapse, while 33 had an IE relapse (CNS = 21; testes = 11; lymph node = 1). In the group as a whole, the median duration of 1st CR was 25 (range 4-77) months; 27 (range 4-77) and 24 (range 2-69) months for the subset with BM and IE relapse, respectively. The median interval between 2nd CR and ABMT was 4 (range 1-14) months for patients with BM relapse, and 6 (range 1-28) months for patients with IE relapse. Marrow purging 29, 30 was used in 45 of 65 BM relapse patients and in 21 of 33 IE relapse patients. A significant difference in the use of TBI conditioning regimen was found between IE and BM relapse patients: 28/33 patients and 31/65, respectively (P = 0.0004). In the subset of IE relapse patients, 17 had previously received prophylactic cranial irradiation (18 Gy) during front-line treatment. For this group the median follow-up was 60 (range 12-118) months. Major details on 2nd CR IE patients are shown in Table 3 .
Ͼ2nd CR group: Fifty-six patients underwent ABMT in Ͼ2nd CR: 38 after two or more isolated and/or combined BM relapses and 18 after two or more IE relapses (site of 1st relapse: CNS = 15; testes = 3). The median duration of 1st CR was 30 (range 3-83) months. This was longer in the BM relapse patients (37, range 4-77 months) than in the IE relapse group (18.5, range 3-59 months) (P = 0.0004). The median interval from achieving last remission to ABMT was 4.5 (range 14-81) months, whereas the median interval from 1st CR to ABMT was 71 (range 10-165) months. Marrow purging 29, 30 was done in 25/38 BM relapse patients and in 8/18 IE relapse patients. A TBI containing regimen was used in 16/38 and 6/18 patients, respectively. For all patients, the median follow-up was 66 (range 12-118) months.
Transplant-related mortality was defined as all deaths other than for leukaemia occurring while the patients were in CR.
Statistical analysis
All information was stored, controlled and analysed by VENUS, an integrated system of software facilities running on an IBM mainframe at the North-East Italian Interuniversity Computing Centre (CINECA). All patients and the 2nd CR or Ͼ2nd CR ABMT groups were tested by 2 test for heterogeneity 32 for the following factors: length of 1st CR, relapse site, purging, TBI. EFS was estimated by the Kaplan-Meier method, 33 as of 31 May 1996. EFS was chosen as the better indicator of procedure effectiveness. Time on study or time to death or relapse was calculated from the day of transplant. Terminal events were relapse and death due to any causes, whichever came first. The logrank test 34 was adopted to assess differences in univariate analysis. Multivariate analysis was conducted according to the Cox regression model. 35 
Results

Survival
Number of relapses did not influence outcome: the 8-year EFS was 34.6% (s.e. 4.9) for patients transplanted in the 2nd and 10.6% (s.e. 5.6) for those transplanted in Ͼ2nd CR, P = 0.11 ( Figure 1 ). In univariate and multivariate analysis better outcome was associated with site of relapse. length of 1st CR (Ͻ30 vs Ͼ30 months = 14.6 vs 24%, P = 0.16), or purging (purged vs unpurged ABMT = 28 vs 29%) influenced EFS.
Ͼ2nd CR group: EFS was not influenced by site of relapse, duration of 1st CR, purging, or TBI.
Transplant-related mortality
Fifteen of the 154 patients (9.7%) died of transplantrelated complications.
2nd CR group: Eight of 98 patients (8.4%) died: two during marrow aplasia (one case of CNS haemorrhage, one of sepsis) and six following marrow engraftment (interstitial pneumonitis in two cases, sepsis in three, CNS haemorrhage in one).
Ͼ2nd CR group: Seven of 56 patients (12%) died: three during marrow aplasia (two sepsis, one liver failure) and four after engraftment (one sepsis, one veno-occlusive disease, one liver failure, and one pulmonary embolism). 
Relapse after transplantation
Ninety-five of the 154 patients (61.6%) experienced a new relapse at a median of 5 (range 1-91) months after ABMT.
2nd CR group:
The relapse rate was 56.1%. In the BM relapse group, 46/65 patients had a new isolated or combined BM relapse and three relapsed only in the CNS at a median of 4 (range 1-30) months after ABMT. In the IE relapse group, 3/33 patients had a BM relapse and two relapsed in the CNS at a median of 7.5 (range 3-15) months after ABMT.
Ͼ2nd CR group: The relapse rate was 71.4%. In the BM relapse group, 24/38 patients relapsed in the BM and three patients in extramedullary sites at a median of 8 (range 2-91) months after ABMT. In the IE relapse group, 7/18 patients relapsed in the BM and four patients in extramedullary sites at a median of 4 (range 1-16) months after ABMT.
Discussion
This co-operative retrospective study analysed results obtained in 154 paediatric patients unndergoing ABMT with varying pre-transplant remission status, with a view to identifying subsets of patients who may benefit from ABMT. In our analysis, the most important prognostic factor was site of relapse in the 2nd CR ABMT group only, while no prognostic factors were identified in the Ͼ2nd CR group. This finding is consistent with our previous report on a smaller group of patients. 31 The markedly better outcome in patients who underwent TBI during conditioning was almost certainly due to the fact that the vast majority of these were IE relapses and there was a different distribution of TBI in the IE and BM relapse groups. In fact, the use of TBI did not influence the prognosis for patients transplanted after isolated or combined marrow relapse. Pre-transplant variables such as duration of 1st CR and longest CR before ABMT, that have been described as the most significant predictors of EFS, 22, 23 did not influence the outcome in this retrospective study. A summary of the most important published data on paediatric ALL autografts in relation to site and time of relapse is presented in Table 4 . The limited number of patients reported prevents definite conclusions on the role of ABMT in the treatment of IE or BM relapse from being drawn. However, the DFS ranges from 33 to 57%, and from 18 to 55% in patients transplanted after an IE or BM relapse, respectively. Unfortunately, no randomised studies have been done to prove the superiority of ABMT over CT as post-remission treatment. However, in our recent retrospective analysis limited to the IE group, ABMT was superior in terms of EFS over conventional chemotherapy in patients who experienced a CNS IE relapse. 43 Thus, the parallel efficacy of ABMT and conventional chemotherapy reported by the BFM group was not confirmed by us. 20 Moreover, even the data on relapse after ABMT (the patients with CNS involvement are considered at higher risk of relapse 44 ) and on TBI toxicity are reassuring in our experience. Only two local relapses were observed and no side-effects, such as major impairment of cognitive capacity or leukoencephalopathy, have been found to date in the patients who had received previous prophylactic cranial irradiation (data not shown). Moreover, it should be taken into account that at least in CNS and systemic relapses conventional treatment (24 Gy cranial or cranio-spinal irradiation and 24 months of chemotherapy) could result in the same late toxicities (growth, thyroid dis-1019 Table 4 Summary of published data on paediatric ABMT orders, leukoencephalopathy and second malignancy) as TBI. 45, 46 A high relapse rate is still observed after ABMT performed after BM relapse, either isolated or combined, regardless of remission status at transplant. Possible mechanisms of relapse include: lack of a GVL effect, the persistence of clonogenic blast cells in the reinfused marrow, and leukaemic cells resistant to the preparatory regimen. Marrow purging techniques are under investigation, but their role in improving EFS is difficult to assess at present. [47] [48] [49] In our experience, EFS was unaffected by purging. Administering biologic modifiers has been carried out in an attempt to elicit an immuno-mediated effect on the blasts [50] [51] [52] [53] or to induce autologous GVHD. 54 The use of such biological response modifiers in the ABMT setting might be useful in the eradication of residual malignant cells and in the prevention of relapse.
In conclusion, our study suggests that ABMT can control early IE disease and could be considered as a therapeutic option in this setting. After several IE relapses, ABMT loses its efficacy. Nevertheless, after a BM relapse or in an advanced stage of disease, few children can be rescued by ABMT. Given the reported equivalent in outcome after conventional chemotherapy or ABMT in the treatment of ALL relapse, 40 a prospective randomised study is needed to analyse which of the two treatments allow a better survival and quality of life.
